Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. More Details
High growth potential with adequate balance sheet.
Share Price & News
How has Flexion Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FLXN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: FLXN underperformed the US Biotechs industry which returned 35.6% over the past year.
Return vs Market: FLXN underperformed the US Market which returned 13.8% over the past year.
Price Volatility Vs. Market
How volatile is Flexion Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StIs Flexion Therapeutics (NASDAQ:FLXN) Using Too Much Debt?
3 weeks ago | Simply Wall StHow Is Flexion Therapeutics' (NASDAQ:FLXN) CEO Compensated?
1 month ago | Simply Wall StCould The Flexion Therapeutics, Inc. (NASDAQ:FLXN) Ownership Structure Tell Us Something Useful?
Is Flexion Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate FLXN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate FLXN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FLXN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: FLXN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FLXN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FLXN is overvalued based on its PB Ratio (32.9x) compared to the US Biotechs industry average (3.3x).
How is Flexion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FLXN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: FLXN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: FLXN's is expected to become profitable in the next 3 years.
Revenue vs Market: FLXN's revenue (38.7% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: FLXN's revenue (38.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FLXN's Return on Equity is forecast to be high in 3 years time
How has Flexion Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FLXN is currently unprofitable.
Growing Profit Margin: FLXN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FLXN is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Accelerating Growth: Unable to compare FLXN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FLXN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: FLXN has a negative Return on Equity (-854.79%), as it is currently unprofitable.
How is Flexion Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: FLXN's short term assets ($246.6M) exceed its short term liabilities ($37.4M).
Long Term Liabilities: FLXN's short term assets ($246.6M) exceed its long term liabilities ($217.9M).
Debt to Equity History and Analysis
Debt Level: FLXN's debt to equity ratio (1322.8%) is considered high.
Reducing Debt: FLXN's debt to equity ratio has increased from 0.3% to 1322.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FLXN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FLXN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 29.5% each year
What is Flexion Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FLXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FLXN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FLXN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FLXN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FLXN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Clayman (68 yo)
Dr. Michael D. Clayman, also known as Mike, M.D., Co-Founded Flexion Therapeutics, Inc. (formerly, Flexion Development Partners, Inc) in 2007 and has been its Chief Executive Officer and President since 20 ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD3.78M) is above average for companies of similar size in the US market ($USD2.02M).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
|Consultant||no data||US$1.36m||0.14% |
|Chief Medical Officer||2.75yrs||US$1.33m||0.24% |
|Chief Financial Officer||2.33yrs||US$3.21m||0.32% |
|VP of Corporate Communications & Investor Relations||no data||no data||no data|
|VP, Legal Affairs & Chief Compliance Officer||4yrs||no data||no data|
|General Counsel & Secretary||3.25yrs||US$1.21m||0.23% |
|Vice President of Sales||4yrs||no data||no data|
|Chief Strategy Officer||4yrs||no data||0.25% |
|Chief Regulatory Officer||4.83yrs||no data||0.26% |
|Senior Vice President of Business Development||1.67yrs||no data||no data|
|Chief Commercial Officer||0.50yr||no data||no data|
Experienced Management: FLXN's management team is considered experienced (3.6 years average tenure).
|Independent Director||12.67yrs||US$153.68k||0.15% |
|Independent Director||9.67yrs||US$151.18k||0.047% |
|Independent Chairman||11.67yrs||US$206.31k||0.063% |
|Independent Director||6.25yrs||US$146.18k||0.020% |
|Independent Director||7.75yrs||no data||0% |
|Independent Director||5.5yrs||US$141.18k||0% |
|Independent Director||4yrs||US$146.18k||0.0074% |
|Independent Director||6.17yrs||US$156.18k||0% |
|Non-Employee Director||0.083yr||no data||no data|
Experienced Board: FLXN's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.4%.
Flexion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Flexion Therapeutics, Inc.
- Ticker: FLXN
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$543.318m
- Shares outstanding: 49.30m
- Website: https://www.flexiontherapeutics.com
Number of Employees
- Flexion Therapeutics, Inc.
- 10 Mall Road
- Suite 301
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FLXN||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Feb 2014|
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculo ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/27 06:37|
|End of Day Share Price||2020/09/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.